Dr. Jack Cush reviews this past week's news on RheumNow.com and suggests a learning plan for those wanting to consume the upcoming ACR Convergence 2023 meeting.
All News
A JAMA systematic review and meta-analysis has showed the use of JAK inhibitors (JAKi) in immune-mediated inflammatory skin diseases was not associated with increased risk of all-cause mortality, major adverse cardiovascular events (MACE), or venous thromboembolism (VTE) (compared to the placebo
Dr. Jack Cush discusses the news, journal articles and regulatory actions. This week we discuss JAKne, DLE and SLE and more.
EULAR has published updated recommendations for the management of systemic lupus erythematosus (SLE) based on new evidence and expert opinion - formulationg five overarching principles and 13 recommendations.
Dr. Jack Cush reviews the news, journal reports and regulatory approvals from this past week on RheumNow.com.
While comorbidities, including an increased cardiovascular (CV) risk, are associated with severe psoriasis, less is known about subclinical CV disease and when it occurs in patients with psoriasis.
Dr. Jack Cush is joined by Dr. Michael Weinblatt as they discuss this weeks news and journal reports, including difficult RA, HLA typing and abatacept responses and new regulatory decisions.
Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow, and introduces our September campaign - "Hard Decisions in RA".
Systemic sclerosis (SSc) sine scleroderma is a unique and rare subset of SSc defined by the absence of skin fibrosis. An analysis of the EUSTAR database suggests systemic disease can be a problem, including interstitial lung disease (>40%) and SSc renal crisis (almost 3%).
Dr. Jack Cush reviews the news and journal reports from RheumNow.com this past week.
Dr. Jack Cush reviews the news and journal reports from the wonderful wide world of Rheumatology. This week:
In research published in Arthritis & Rheumatology, investigators developed and validated a tool called PRESTO that identif
IL-23 inhibitors are approved for the treatment of psoriasis and psoriatic arthritis; a single center real-world observational study shows three commercially available IL-23 inhibitors have high and similar drug survival and effectiveness in difficult-to-treat psoriasis and PsA.
Link Between Vitamin D and Psoriasis Severity
More than eight million people in the U.S. experience psoriasis, a condition in which skin cells build up and form itchy dry patches. A person’s vitamin D levels could play an important role in psoriasis severity, according to one of the largest studies to date.
